Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Rubin DT, Torres J, Regueiro M, Reinisch W, Prideaux L, Kotze PG, Tan FH, Gardiner S, Mundayat R, Cadatal MJ, Ng SC February 19, 2022 ECCO 2022 Ulcerative Colitis

Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme

View Presentation
Poster
Rubin DT, Vavricka SR, Armuzzi A, Dubinsky MC, Sharara AI, Modesto I, Fellmann M, Liguori G, Lawendy N, Cadatal MJ, Lichtenstein GR February 19, 2022 ECCO 2022 Ulcerative Colitis

Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

View Presentation
Oral Presentation
Hassan-Zahraee M, Ye Z, Xi L, Banerjee A, He W, Dushin E, Lee J, Altintas E, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Vincent M, Hyde C, Longman R, Hung KE February 19, 2022 ECCO 2022 Ulcerative Colitis

Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in ulcerative colitis (UC) (phase 2 Vibrato study)

View Presentation
Poster
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM February 19, 2022 ECCO 2022 Ulcerative Colitis

Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE Open

View Presentation
Poster
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM February 19, 2022 ECCO 2022 Ulcerative Colitis

Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

View Presentation
Poster
Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT February 19, 2022 ECCO 2022 Ulcerative Colitis

Sustained improvement in health-related quality of life outcomes in patients with Ulcerative Colitis with long-term tofacitinib treatment in the open-label extension study, OCTAVE Open

View Presentation
Oral Presentation
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Guo X, Mundayat R, Su C, Panés J February 19, 2022 ECCO 2022 Ulcerative Colitis

Tofacitinib for the treatment of ulcerative colitis: an integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

View Presentation
Poster
Rubin DT, Vavricka SR, Armuzzi A, Dubinsky MC, Sharara AI, Modesto I, Fellmann M, Liguori G, Lawendy N, Cadatal MJ, Lichtenstein GR May 24, 2022 DDW 2022 Ulcerative Colitis

Efficacy and safety of tofacitinib in ulcerative colitis patients with extraintestinal manifestations in OCTAVE Open

View Presentation
Oral Presentation
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panés J, Yarur A, Ritter T, Baert F, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG May 24, 2022 DDW 2022 Ulcerative Colitis

Etrasimod 2 mg Once Daily as Treatment for Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

View Presentation
Oral Presentation
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Guo X, Mundayat R, Su C, Panés J May 24, 2022 DDW 2022 Ulcerative Colitis

Tofacitinib for the treatment of ulcerative colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials

View Presentation